Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

It wasn't so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders. CagriSema, an investigational weight loss medicine, performed well in ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy. That said, despite possible ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...